http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10563267-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d1ff9c2c1baad28fcc4f48da2e36595 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78941ed5a01bfbcd48376e1fdb485b19 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2017-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ba777e96e9aa8d15c7b1294c0c474c8 |
| publicationDate | 2020-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10563267-B2 |
| titleOfInvention | Polymorphism biomarkers predict clinical outcomes of cancer patients receiving regorafenib |
| abstract | Methods are provided for determining whether a cancer patient is likely or not likely to experience HFSR (hand foot skin reaction) from a therapy comprising administration of an effective amount of regorafenib or an equivalent thereof, the methods including screening a biological sample isolated from the patient for the rs2280789 polymorphism, and/or the rs3817655 polymorphism. Methods are further provided for identifying the clinical outcome of cancer patients following a therapy comprising regorafenib or an equivalent thereof, the methods entailing screening a biological sample isolated from the patient for the rs7527092 polymorphism, and/or rs2071559 polymorphism. After determining if a patient is likely to be successfully treated, the disclosure also provides methods for treating the patient. |
| priorityDate | 2016-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 495.